Reuters logo
BRIEF-Acorda discontinues Tozadenant development program
November 20, 2017 / 12:15 PM / 24 days ago

BRIEF-Acorda discontinues Tozadenant development program

Nov 20 (Reuters) - Acorda Therapeutics Inc:

* Acorda discontinues tozadenant development program

* Says also ‍immediately discontinuing dosing of all participants currently enrolled in its tozadenant studies​

* Acorda Therapeutics - ‍decision based on new information obtained from phase 3 program related to previously disclosed agranulocytosis and associated serious adverse events​

* Acorda Therapeutics - concluded that it could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety​

* Says it ‍has informed regulatory authorities and trial investigators regarding orderly closure of ongoing studies​

* Acorda Therapeutics - ‍over 90 percent of participants in placebo-controlled phase 3 efficacy and safety study, cl-05, have completed study​

* Acorda Therapeutics - ‍expects data from the participants in q1 of 2018 and to present these at appropriate medical/scientific venues​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below